Top

Published in:

Open Access 01-12-2022 | Food Allergy | Short report

Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice

Authors: Jay Portnoy, Christina E. Ciaccio, Janet Beausoleil, George Du Toit, Stanley Fineman, Stephen A. Tilles, June Zhang, Claire Lawrence, Mohamed Yassine, S Shahzad Mustafa

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2022

Abstract

Background

Shared learnings from the early use of novel therapies can aid in their optimization. The recent introduction of peanut oral immunotherapy (peanut OIT; Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]) for peanut allergy addresses a significant unmet need but also highlights the requirement for consideration of several factors by both prescribers and patients.

Objective

To provide guidance for prescribers of licenced peanut OIT to facilitate treatment delivery and improve outcomes.

Methods

Clinicians with experience of licenced peanut OIT (United States n = 6, United Kingdom n = 1) participated in a series of interviews and group discussions designed to elicit tips for successful implementation.

Results

Clinicians identified 8 tips that were considered the most relevant, practical, and impactful for prescribers of Peanut (Arachis hypogaea) Allergen Powder-dnfp: (1) preparing to provide treatment, (2) assessing the medical indication for treatment and (3) shared decision making, (4) staff education, (5) establishing office processes, (6) managing patient expectations and using anticipatory guidance, (7) optimising adherence and (8) maintaining flexibility throughout the treatment process. In addition, a range of supporting materials (e.g., checklists and action plans) are provided.

Conclusion

The introduction of a novel therapy often requires healthcare providers to modify or adopt practices to effectively employ the treatment. The provision of guidance based upon early real-world experiences of licenced peanut OIT may help inform clinical practice and improve treatment outcomes.

Available only for authorised users

Tham EH, Leung DYM. How different parts of the world provide new insights into food allergy. Asthma Immunol Res. 2018. https://doi.org/10.4168/aair.2018.10.4.290.CrossRef

Gupta RS, Warren CM, Smith BM, Blumenstock JA, Jiang J, Davis MM, et al. The public health impact of parent-reported childhood food allergies in the United States. Pediatrics. 2018. https://doi.org/10.1542/peds.2018-1235.CrossRefPubMedPubMedCentral

Mahr TA, Lieberman JA, Haselkorn T, Damle V, Ali Y, Chidambaram A, et al. Characteristics of peanut allergy diagnosis in a us health care claims database (2011–2017). J Allergy Clin Immunol Pract. 2020. https://doi.org/10.1016/j.jaip.2020.12.020.CrossRefPubMed

Nwaru BI, Hickstein L, Panesar SS, Roberts G, Muraro A, Sheikh A. Prevalence of common food allergies in Europe: A systematic review and meta-analysis. Allergy. 2014. https://doi.org/10.1111/all.12423.CrossRefPubMed

Lieberman JA, Gupta RS, Knibb RC, Haselkorn T, Tilles S, Mack DP, et al. The global burden of illness of peanut allergy: a comprehensive literature review. Allergy Eur J Allergy Clin Immunol. 2020. https://doi.org/10.1111/all.14666.CrossRef

DunnGalvin A, Gallop K, Acaster S, Timmermans F, Regent L, Schnadt S, et al. APPEAL-2: A pan-European qualitative study to explore the burden of peanut-allergic children, teenagers and their caregivers. Clin Exp Allergy. 2020. https://doi.org/10.1111/cea.13719.CrossRefPubMedPubMedCentral

Wang J, Johnston DT, Lieberman JA, Birchwood C, Acaster S, de Vries J, et al. Impact of peanut allergy on quality of life: baseline results from PALISADE, a Phase 3, double-blind, placebo-controlled trial for AR101 oral immunotherapy. J Allergy Clin Immunol. 2019. https://doi.org/10.1016/j.jaci.2018.12.471.CrossRefPubMedPubMedCentral

Nowak-Wegrzyn A, Hass S, Tilles S, Donelson S, Robison D, Norrett K, et al. Peanut allergy burden survey: impact of peanut allergy on global quality of life in adolescent patients. J Allergy Clin Immunol. 2020. https://doi.org/10.1016/j.jaci.2019.12.470.CrossRefPubMed

U.S. Food and Drug Administration. PALFORZIA | FDA. https://www.fda.gov/vaccines-blood-biologics/allergenics/palforzia. Accessed 15 Sep 2020.

10.

European Medicines Agency. SUMMARY OF PRODUCT CHARACTERISTICS: PALFORZIA. 2020. https://www.ema.europa.eu/en/documents/assessment-report/palforzia-epar-public-assessment-report_en.pdf. Accessed 16 Feb 2022.

11.

Wasserman RL, Factor J, Windom HH, Abrams EM, Begin P, Chan ES, et al. An approach to the office-based practice of food oral immunotherapy. J Allergy Clin Immunol Pract. 2021. https://doi.org/10.1016/j.jaip.2021.02.046.CrossRefPubMed

12.

Leonard SA, Laubach S, Wang J. Integrating oral immunotherapy into clinical practice. J Allergy Clin Immunol. 2021. https://doi.org/10.1016/j.jaci.2020.11.011.CrossRefPubMed

13.

Greenhawt MJ, Vickery BP. Allergist-reported trends in the practice of food allergen oral immunotherapy. J allergy Clin Immunol Pract. 2015. https://doi.org/10.1016/j.jaip.2014.06.023.CrossRefPubMed

14.

Patrawala M, Shih J, Lee G, Vickery B. Peanut Oral Immunotherapy: a current perspective. Curr Allergy Asthma Rep. 2020. https://doi.org/10.1007/s11882-020-00908-6.CrossRefPubMedPubMedCentral

15.

Patrawala S, Ramsey A, Capucilli P, Tuong L-A, Vadamalai K, Mustafa SS. Real-world adoption of FDA-approved peanut oral immunotherapy with Palforzia. J Allergy Clin Immunol Pract. 2022. https://doi.org/10.1016/j.jaip.2021.12.022.CrossRefPubMed

16.

Greiwe J, Oppenheimer J, Bird JA, Fleischer DM, Pongracic JA, Greenhawt M. AAAAI work group report: trends in oral food challenge practices among allergists in the United States. J Allergy Clin Immunol Pract. 2020. https://doi.org/10.1016/j.jaip.2020.07.035.CrossRefPubMedPubMedCentral

17.

Bird JA, Leonard S, Groetch M, Assa A, Cianferoni A, Clark AS, et al. Conducting an oral food challenge: an update to the adverse reactions to foods committee work group report. J Allergy Clin Immunol Pract. 2009. https://doi.org/10.1016/j.jaip.2019.09.029.CrossRef

18.

Aimmune Therapeutics INC. PALFORZIA REMS. https://www.palforziarems.com/#Main. Accessed 3 Mar 2021.

19.

Aimmune Therapeutics. Educational Risk Minimisation Materials. https://www.aimmune.co.uk/healthcare-professionals. Accessed 16 Feb 2022.

20.

Greenhawt M, Shaker M, Wang J, Oppenheimer JJ, Sicherer S, Keet C, et al. Peanut allergy diagnosis: a 2020 practice parameter update, systematic review, and GRADE analysis. J Allergy Clin Immunol. 2020. https://doi.org/10.1016/j.jaci.2020.07.031.CrossRefPubMed

21.

Van Der Velde JL, Flokstra-De Blok BMJ, De Groot H, Oude-Elberink JNG, Kerkhof M, Duiverman EJ, et al. Food allergy-related quality of life after double-blind, placebo-controlled food challenges in adults, adolescents, and children. J Allergy Clin Immunol. 2012. https://doi.org/10.1016/j.jaci.2012.05.037.CrossRefPubMed

22.

Vickery BP, Vereda A, Casale TB, Beyer K, Du TG, Hourihane JO, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1812856.CrossRefPubMed

23.

Begin P, Chinthrajah RS, Nadeau KC. Oral immunotherapy for the treatment of food allergy. Hum Vaccin Immunother. 2014. https://doi.org/10.4161/hv.29233.CrossRefPubMedPubMedCentral

24.

Jagdis A, Berlin N, Barron C, Giruparajah M, Leader N, Maclachlan S, et al. Effect of ketotifen premedication on adverse reactions during peanut oral immunotherapy. Allergy Asthma Clin Immunol. 2014. https://doi.org/10.1186/1710-1492-10-36.CrossRefPubMedPubMedCentral

25.

Wasserman RL, Hague AR, Pence DM, Sugerman RW, Silvers SK, Rolen JG, et al. Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients. J Allergy Clin Immunol Pract. 2019. https://doi.org/10.1016/j.jaip.2018.05.023.CrossRefPubMed

26.

Varshney P, Steele PH, Vickery BP, Bird JA, Thyagarajan A, Scurlock AM, et al. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol. 2009. https://doi.org/10.1016/j.jaci.2009.09.042.CrossRefPubMedPubMedCentral

27.

Niggemann B, Beyer K. Factors augmenting allergic reactions. Allergy. 2014. https://doi.org/10.1111/all.12532.CrossRefPubMed

Title: Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice
Authors: Jay Portnoy
Christina E. Ciaccio
Janet Beausoleil
George Du Toit
Stanley Fineman
Stephen A. Tilles
June Zhang
Claire Lawrence
Mohamed Yassine
S Shahzad Mustafa
Publication date: 01-12-2022
Publisher: BioMed Central
Keyword: Food Allergy
Published in: Allergy, Asthma & Clinical Immunology / Issue 1/2022
Electronic ISSN: 1710-1492
DOI: https://doi.org/10.1186/s13223-022-00671-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice

Abstract

Background

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Associations between food allergy, country of residence, and healthcare access

AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy

Intravenous immunoglobulins improve live birth rate among women with underlying immune conditions and recurrent pregnancy loss: a systematic review and meta-analysis

It takes a village: perceptions of Winnipeg parents, students, teachers and school staff regarding the impact of food allergy on school-age students and their families

Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies

Drug-induced hypersensitivity syndrome induced by propylthiouracil: case report and literature review